$MYGN on NASDAQ
February 27, 2024
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
February 27, 2024
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 21, 2024
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 01, 2024
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 30, 2024
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 18, 2024
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 09, 2024
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 03, 2024
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 20, 2023
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
November 20, 2023
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 16, 2023
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 09, 2023
Myriad Genetics to Participate in Stephens Annual Investment Conference
November 08, 2023
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 06, 2023
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
November 01, 2023
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
October 31, 2023
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
October 26, 2023
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
September 28, 2023
BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
September 28, 2023
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
September 19, 2023
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
September 19, 2023
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
September 18, 2023
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 06, 2023
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
September 06, 2023
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
September 05, 2023
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
August 22, 2023
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
August 17, 2023
Myriad Genetics to Host Investor Day on September 19, 2023
August 15, 2023
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
August 08, 2023
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
August 07, 2023
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
August 03, 2023
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
July 27, 2023
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
July 24, 2023
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
July 06, 2023
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
June 12, 2023
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
June 07, 2023
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
June 01, 2023
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
May 31, 2023
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
May 24, 2023
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 08, 2023
Myriad Genetics Earns 2023 Great Place to Work Certification™
May 03, 2023
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
May 02, 2023
Myriad Genetics to Participate in BofA Securities Healthcare Conference
April 26, 2023
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
April 19, 2023
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
April 18, 2023
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
April 12, 2023
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
March 02, 2023
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
- No Recent Filings Found.
